Submissions for variant NM_000138.5(FBN1):c.3931T>A (p.Tyr1311Asn)

gnomAD frequency: 0.00001  dbSNP: rs1406315227

Total submissions: 5

Submitter	RCV	SCV	Clinical significance	Condition	Last evaluated	Review status	Method	Comment
Human Genome Sequencing Center Clinical Lab, Baylor College of Medicine	RCV001258188	SCV001435077	uncertain significance	Marfan syndrome		criteria provided, single submitter	clinical testing
AiLife Diagnostics, AiLife Diagnostics	RCV002223293	SCV002501289	uncertain significance	not provided	2022-02-02	criteria provided, single submitter	clinical testing
Fulgent Genetics, Fulgent Genetics	RCV002486004	SCV002788602	uncertain significance	Ectopia lentis 1, isolated, autosomal dominant; Marfan syndrome; MASS syndrome; Stiff skin syndrome; Weill-Marchesani syndrome 2, dominant; Acromicric dysplasia; Geleophysic dysplasia 2; Progeroid and marfanoid aspect-lipodystrophy syndrome	2021-10-16	criteria provided, single submitter	clinical testing
Labcorp Genetics (formerly Invitae), Labcorp	RCV002570635	SCV003446477	likely pathogenic	Marfan syndrome; Familial thoracic aortic aneurysm and aortic dissection	2023-12-30	criteria provided, single submitter	clinical testing	This sequence change replaces tyrosine, which is neutral and polar, with asparagine, which is neutral and polar, at codon 1311 of the FBN1 protein (p.Tyr1311Asn). This variant is present in population databases (no rsID available, gnomAD 0.0009%). This missense change has been observed in individual(s) with clinical features of Marfan syndrome (PMID: 25652356). ClinVar contains an entry for this variant (Variation ID: 979123). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt FBN1 protein function with a positive predictive value of 95%. This variant disrupts the p.Tyr1311 amino acid residue in FBN1. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 27906200, 31131229). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic.
Women's Health and Genetics/Laboratory Corporation of America, LabCorp	RCV004690039	SCV005184485	uncertain significance	not specified	2024-05-28	criteria provided, single submitter	clinical testing	Variant summary: FBN1 c.3931T>A (p.Tyr1311Asn) results in a non-conservative amino acid change located in the EGF-like domain (IPR000742) of the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 4e-06 in 251280 control chromosomes. c.3931T>A has been reported in the literature in two individuals in one family affected with clinical features of Marfan Syndrome (Baudhuin_2015). These data indicate that the variant may be associated with disease. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. The following publication have been ascertained in the context of this evaluation (PMID: 25652356). ClinVar contains an entry for this variant (Variation ID: 979123). Based on the evidence outlined above, the variant was classified as VUS-possibly pathogenic.